DragonFly M2 Pivotal Study

NCT ID: NCT07243197

Last Updated: 2025-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-15

Study Completion Date

2031-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects.The safety and effectiveness of the first-generation device(Dragonfly Transcatheter Mitral Valve Repair System)have been previously demonstrated. This study aims to further confirm the safety and effectiveness of the new device following structural optimization based on the first-generation design.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicentric clinical investigation.

Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team .

After signing an informed consent form, subjects in the experimental group will undergo the transcatheter mitral valve repair procedure using the DragonFly M2 Transcatheter Mitral Valve Clip System. All subjects were followed up immediately after procedure, before discharge, 30 days , 6 months, 12 months after procedure, and 2, 3, 4, and 5 years after procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve (MV) Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DragonFly M2 Transcatheter Mitral Valve Repair System

Transcatheter mitral valve repair with the DragonFly M2 System in patients with degenerative mitral regurgitation

Group Type EXPERIMENTAL

DragonFly M2 Transcatheter Mitral Valve Repair System

Intervention Type DEVICE

Edge-to-edge repair with DragonFly M2 System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DragonFly M2 Transcatheter Mitral Valve Repair System

Edge-to-edge repair with DragonFly M2 System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1.≥ 18 years old. 2.Moderate to severe (3+) or severe (4+) chronic DMR determined by transthoracic echocardiography.

* Transseptal catheterization is determined to be feasible by the Investigator.
* Patients have been informed of the nature of the study, understand the purpose of the clinical trial, voluntarily participate in the study, and sign the ICF.

Exclusion Criteria

1)Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2) The presence of other severe heart valve disease requiring surgical intervention.

3\) Prior mitral valve leaflet surgery or transcatheter mitral valve intervention.

* Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
* In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hangzhou Valgen Medtech Co., Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiangbin Pan

Role: PRINCIPAL_INVESTIGATOR

Chinese Academy of Medical Sciences, Fuwai Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fuwai Hospital Chinese Academy of Medical Sciences

Shenzhen, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bo Liu

Role: CONTACT

+86 13001980902

Xiaoxu Yang

Role: CONTACT

+8618910330079

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiangbin Pan, MD, PH.D

Role: primary

+8618010155168

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DragonFly-M2 01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

J-Valve Transfemoral Pivotal Study
NCT06455787 RECRUITING NA
The China Mviv Registry
NCT05925335 UNKNOWN NA
Clinical Trial in China
NCT05580952 UNKNOWN NA